autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides

Cell therapyexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2016 (NCT02903537)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • SphingomyelinImmunity, desensitized

    Sphingomyelin immunity, desensitized

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02903537Phase 1Sep 1, 2016Badalona Hospital Germans Trias i Pujol, Clinica Universidad de Navarra
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Badalona Hospital Germans Trias i PujolAcademic/Hospital1112016
Clinica Universidad de NavarraAcademic/Hospital1012016
2 organizations
Page 1 / 1